Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Custom Recombinant Fab Antibody Production and Purification

Active

Federal

Response Deadline08/24/2026, 12:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

A custom recombinant Fab antibody based on the HuCAL platform is to be manufactured, purified, and tested in a quantity of 2.8 milligrams solely for in vitro research purposes. The work encompasses the full lifecycle of antibody production including expression in a suitable host system, followed by affinity chromatography for high-purity isolation, and concludes with rigorous ELISA-based functional and specificity assays to validate performance. The contract is structured as a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 261421 indicating classification within biological product manufacturing. The solicitation was posted on August 7, 2026, with a formal response deadline of August 24, 2026, and performance is expected to occur without geographic restriction. The requirement specifies strict adherence to scientific benchmarks for purity and function, with no set-aside designation applied, and the deliverable is intended exclusively for non-clinical research applications.

General Info

Manufacture 2.8 mg HuCAL Fab antibody for in vitro research under NIH subcontract with ELISA validation.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

261421View NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedAug 7

subcontract

Response DeadlineAug 24

Submission deadline

Response Deadline

08/24/2026, 12:00:00 PM UTCin 16 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Manufacture, purify, and test 2.8 mg of a custom HuCAL recombinant Fab antibody for in vitro research use. Requires expression, affinity chromatography purification, and ELISA-based functional and specificity testing.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

Laboratory Animal Supply and Acclimation

Other Chemical and Allied Products Merchant Wholesalers

POSTED

DEADLINE

Preclinical Data Management and Reporting

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Necropsy and Tissue Preservation Services

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Dose Formulation and Compound Handling

Research and Development in Biotechnology

POSTED

DEADLINE

Preclinical Rodent Toxicity Study Execution

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Regulatory and Data Compliance SupportThe contract titled Regulatory and Data Compliance Support is a subcontract issued by the National Institutes of Health under the Department of Health and Human Services, focused on ensuring all study documentation, raw data, and final reports adhere to Federal Acquisition Regulation standards, applicable data rights provisions, strict confidentiality protocols, and government audit requirements. The work is intended to support compliance across the full lifecycle of research activities, mandating rigorous documentation practices and secure data handling procedures to meet federal oversight standards. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and is classified under NAICS code 541611 for administrative management and general management consulting services. The place of performance and point of contact details are not specified, but performance is expected to align with federal guidelines regardless of location, and interested parties must submit proposals before the deadline to be considered for award.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Pharmacokinetic Data Analysis and ReportingThe contract entails the analysis of plasma concentration-time data to determine pharmacokinetic parameters and generate detailed concentration-time curves, with all results delivered in a structured Excel report accompanied by a narrative summary that interprets the findings. The work is focused on quantitative evaluation of drug behavior in the body, requiring precise computational methods and regulatory-compliant reporting standards to ensure accuracy and reproducibility. The deliverables must be clearly formatted, scientifically sound, and tailored for use in regulatory submissions or internal R&D decision-making. This is a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 541690 indicating specialized scientific and technical consulting services. The opportunity was posted on August 7, 2026, with a response deadline of August 24, 2026, and no set-aside provisions are specified. While the place of performance and point of contact details are not provided, the work is expected to be performed remotely or under flexible arrangements, consistent with the nature of data analysis tasks. The contracting entity is seeking qualified contractors with demonstrated expertise in pharmacokinetic modeling and data reporting to support ongoing research initiatives.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Bioanalytical Assay Development and QuantificationThe contract requires the development and performance of liquid chromatography-tandem mass spectrometry assays to quantify plasma concentrations of three small-molecule inhibitors and their metabolite 1-MNA in mouse plasma samples. The work involves establishing validated methods for accurate and precise measurement of these compounds, ensuring reliability for preclinical pharmacokinetic studies. The assays must be capable of detecting low concentrations with appropriate sensitivity, specificity, and reproducibility across the expected concentration range in biological matrices. This subcontract is issued under the NAICS code 541380, indicating a focus on scientific and technical consulting services, and is associated with the National Institutes of Health under the Department of Health and Human Services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026. The place of performance and specific location details are not provided, and no set-aside provisions are specified. The work is intended to support biomedical research activities, likely aimed at evaluating drug metabolism and exposure profiles in mouse models.

Testing Laboratories and Services

POSTED

DEADLINE

Preclinical Pharmacokinetic (PK) Study ExecutionThe contract involves the execution of preclinical pharmacokinetic studies in mice to evaluate the absorption, distribution, metabolism, and excretion of three lead compounds following both intravenous and oral administration. Blood samples will be collected at ten distinct time points across a 24-hour period to generate detailed concentration-time profiles for each compound, enabling the calculation of key pharmacokinetic parameters such as bioavailability, clearance, and half-life. The work is to be performed under a subcontract arrangement with the National Institutes of Health, operating under the Department of Health and Human Services, and is classified under NAICS code 541940 for other scientific and technical consulting services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and the studies are expected to be conducted at an unspecified location designated by the contracting entity. The scope requires strict adherence to standardized protocols for animal handling, sample processing, and data collection to ensure regulatory compliance and scientific rigor.

Veterinary Services

POSTED

DEADLINE

Confidential Research Reporting and AnalysisThe contract requires the generation of detailed scientific reports focused on univariate and multivariate correlation analyses of drug response patterns across a panel of cell lines, ensuring rigorous analytical standards and adherence to strict confidentiality protocols. All work must comply with NCATS publication restrictions, meaning results cannot be publicly disclosed or published without explicit authorization, and all data handling must preserve the proprietary and sensitive nature of the underlying biological and pharmaceutical information. The project is structured as a subcontract under the National Institutes of Health, operating within the Department of Health and Human Services, with the NAICS code 541715 indicating it falls under scientific research and development services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and performance is expected to be carried out under the oversight and guidelines of the NCATS program, though no specific location or point of contact is provided.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Compound Handling and Dilution PreparationThe contract requires the recipient to receive a test compound in the form of a 1000x DMSO stock solution and precisely prepare an 8-point, 3-fold dilution series for utilization in the PRISM assay. The preparation must ensure the stability of the compounds throughout the dilution process and maintain full traceability of each step to guarantee experimental reproducibility and data integrity. All procedures must adhere to standardized protocols to avoid contamination, degradation, or measurement errors that could compromise assay outcomes. The work is classified as a subcontract under NAICS code 325412 and is issued by the National Institutes of Health under the Department of Health and Human Services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026. The performance location and specific contact details are not provided, but the scope is strictly focused on compound handling and serial dilution preparation without additional responsibilities such as assay execution or data analysis. Accurate documentation, quality control measures, and compliance with good laboratory practices are implicitly required to meet the contract’s technical objectives.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Data Management and Portal SubmissionThe contract requires the compilation, validation, and secure submission of raw viability data, quality metrics, and analytical outputs through the PRISM Portal within four months after study completion, with strict adherence to specified formatting standards to ensure compliance and data integrity. All submissions must be transmitted securely and meet predefined technical requirements to facilitate accurate processing and regulatory alignment. This subcontract, posted by the National Institutes of Health under the Department of Health and Human Services with a NAICS code of 541611, is open for response until August 24, 2026, and focuses on data management activities supporting federal research initiatives. While no set-aside type is designated, the performance location and point of contact details are unspecified, indicating that the work may be conducted remotely or at the contractor’s discretion, provided all submission deadlines and portal protocols are strictly followed.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE